<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618784</url>
  </required_header>
  <id_info>
    <org_study_id>K0202</org_study_id>
    <nct_id>NCT03618784</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid
      arthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1: Single center, open Phase 2a : Multi-center, randomized, double-blind, parallel,
      placebo Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate
      to Severe Rheumatoid arthritis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of FURESTEM-RA Inj. - number of adverse events</measure>
    <time_frame>4 weeks follow-up after treatment</time_frame>
    <description>Evaluate the number of adverse events Safety of FURESTEM-RA Inj.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by DAS(Disease activity scores)28-ESR</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
    <description>DAS range is from ≥ 3.2 (inactive) , ＞3.2 but ≤ 5.1(moderate), ＞5.1(very active)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by KHAQ(Korean Health assessment questionnaire)</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
    <description>KHAQ range is from 0 (clear) to 60 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by CDAI (clinical disease activity index)</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
    <description>CDAI range is from 0 (clear) to 76 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by 100mm Pain VAS(Visual analogue scale)</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
    <description>100mm Pain VAS range is from 0 (clear) to 100 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of use and consumed amount of rescue medicine</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokine(TNF-a, Interleukin (IL)-1b, IL-4,IL-6,IL-8,IL-10,IL-13,IL-17A,IL-21,IL-22)</measure>
    <time_frame>16 weeks follow-up after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>FURESTEM-RA Inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FURESTEM-RA Inj</intervention_name>
    <description>The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.
Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.
Dose level 1: 5.0 x 10^7 cells /body 3 repeated intravenous injection at 4 week intervals
Dose level 2: 1.0 x 10^8 cells /body 3 repeated intravenous injection at 4 week intervals</description>
    <arm_group_label>FURESTEM-RA Inj.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sterile saline</intervention_name>
    <description>sterile saline 3 repeated intravenous injection at 4 week intervals
Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.
Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. of either gender, 19-80years old

          2. Subjects must be diagnosed according to the 2010 ACR/EULAR criteria for at least 12
             weeks duration.

          3. Subjects must be diagnosed with ACR functional class I. II, III

          4. ≥ 6 tender joints, swollen joints (68 joint count) at Screening

          5. Subject who has moderate to severe disease activity (DAS28-ESR&gt;3.2) on screening visit

          6. History of treatment for one of conventional DMARDs or biologic DMARDs or JAK
             inhibitors AND people diagnosed with either (a) or (b) by a trained person, or people
             that have potential side effects thus not qualified from using biologic DMARDs.

               1. people that have no effect with permitted dose taking for more than 3 months

               2. people with a history of side effects of relevant treatment

          7. Subjects must be taking cDMARDs(including methotrexate, sulfasalazine,
             hydroxychloroquine, leflunomide) or tacrolimus of stable dose More than 12 weeks
             before baseline visit and be willing to remain on stable dose throughout the study

          8. If subject is currently administering steroids everyday, when steroid dose is
             converted into prednisolone oral dose, the subject should take a stable
             dose(≤10mg/day) over 4 weeks on screening visit

          9. In case of taking NASAIDs, Tramadol patients with stable amount of medication at least
             2 weeks before screening visit.

         10. During screening visit , patients with an ESR result of 28mm/hr; patients with a
             1.0mg/dL or greater in a CRP testing

         11. Subject who understands and voluntarily sign an informed consent form

        Exclusion Criteria:

          1. Subjects who is diagnosed ACR function class IV Rheumatoid Arthritis

          2. Patients who are judged by the PI(or Sub-I) to be unable to participate in clinical
             trials due to uncontrolled or unstable cardiovascular disease or severe blood disease

          3. Subjects who has AIDS, other rheumatic disease(Crohn's disease, systemic lupus
             erythematosus, lyme disease, psoriatic arthritis, spondylarthropathy, infectious or
             reactive arthritis, reiter's syndrome, etc.)

          4. Prior use of bDMARDs, within the following windows prior to baseline

               -  24 weeks for Rituximab

               -  10 weeks for Abatacept, Golimumab, Certolizumab pegol, Tocilizumab

               -  7 weeks for Infliximab

               -  4 weeks for Etanercept

               -  3 weeks for Tofacitinib, Baricitinib

          5. Subject who has history of hypersensitivity, heavy metal poisoning, etc. to drugs
             which is composed of similar components.

          6. Subject who has treated intravenous, intramuscular steroid injection within 2 weeks
             before screening visit or intra-articular steroid injection within 4 weeks before
             screening visit

          7. Subject who has administered ACTH(adrenocorticotropic hormone) agents within 4 weeks
             before screening visit

          8. Subject who has undergone administration of any investigational drug within 30 days
             before screening visit.

          9. Use of prohibited medication or inability to avoid the use of prohibited medication
             during the study

         10. Pregnant, breast-feeding women

         11. A female or male in their childbearing ages that is not willing to take proper
             contraceptive methods during a study

         12. Subject who has sever dyshepatia (Serum creatinine level ≥ 1.7mg/dl)

         13. Subject who has severe renal dysfunction (ALT/AST/bilirubin value ≥ 2 upper limit of
             the normal range at screening test)

         14. Any other condition which the PI Judges would make patient unsuitable for study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae Hun Jung</last_name>
    <email>jhjung@kangstem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangdong Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ran Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hae-rim Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yeo-na Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul Hospital attached to Soonchunhyang University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hyeon-suk Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul national University Boramae</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin-gyun Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FURESTEM-RA Inj.</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

